Retail makes it sound as if the FDA invited them, etc... The responsibility to adjudicate lies in the hands of the FDA. The FDA always makes the recommendation.
Valstar is 10% DFS not 10% CRR - agreed on Safety profile.
FDA dept. processing filing approvals is not the same as team providing recommendation. I've read retail bloggers saying the FDA invited Telesta, etc. - it is Telesta that initiated conversations with FDA and sought recommenation.
Commercialization team is always (read always) put in place in anticipation of approval, cannot be read as mark of confidence - it's procedural. This is again retail talk.
There are numerous instances of hedgies buying at market w/o warrants. Robert Frost, Randall Kirk, John Pappajohn...
Why did ENDO walk away from MCNA partnering? what are the details around the trial you talk about?
The is the likelihood of the FDA recommending the 2nd Phase 3. Most clinical trials require two Phase 3 trials to be run, typically sequentially and sometimes concurrently. Some trials have a single Phase 3 declared at the start as a pivotal Phase 3. In this case the 1st Phase 3 was not initiated as a pivotal trial.
The first Phase 3 enrolled 129 patients and took 4&1/2 years to complete.
There is a reason the stock price is cheap.
drdarious, your statement makes me chuckle - each year around this time over the past 3 years someone on the board has said the exact same thing! 2016, 2015, 2014, 2013 will be a huge year for CTIX. then in March people say "can't wait for CTIX to present at this year's June ASCO". Hopefully our wishes come true as you project.
You're right- science should carry the day. But with the pps on the skids, Leo seems to be losing it - I wouldn't have a problem with a more dyed in the wool type than one that offers interviews on iHub. Why would anyone have a problem with a reverse split per se? Again, I'm not agruing for one if the results from strong science can obviate it.
StreetSweeper's already taken a swipe and Mako & Gum-boy can't be far behind. But I think AVXL's the real deal if any of you have read the details. The real test is partnership which they claim to secure within 6 months of the Nov 7 release. If they snag big fish they're golden. It's the time in between when you have to do your DD ad decide whether to get in or not.
KM scientific acumen is why I'm in CTIX. The guys a pharma-genius. It took him a snap to create stable B-ABSSSI at room temp. while the Poly guys fumbled themselves into BK. Not so sure his streetsmarts are any better than Leo's though, the way they handled the DC conference no-show
No question Leo has been way less than perfect time and again but given the whole show's been run by just him & KM, he's had a heck of a lot to do! Both of them.
But it raises the question, why are they killing themselves juggling like crazy and running the risk of jeopardizing their enterprise? I know it's all about the shares and control they don't want to lose but there's got to be a way to put together a world-class BOD and Scientific Advisory Committee and still retain control. It's clear they are fighting against it and probably believe (not wrongly) solid science should carry itself through FDA, etc. (Hopefully someone will bring it up at the shareholders' meeting. It can't all be money as Leo has compared CTIX's potential to REGN! He will have more money than he can dream of with half his shares if our share price ever gets close.
Many iHubbers have observed developments over at AVXL, a once-tried-and-failed effort that has been transformed (so far so good) through the efforts of a very enterprising CEO Chris Missling. He has pulled together a galaxy of luminaries in their field (turns heads towards the co.) and just executed a NASDAQ uplist. It's been astounding to watch him control the timing and sequence of events so far to near perfection. Leo doesn't hold a candle to his strategic acumen. The reverse split came as a complete surprise and wasn't rinsed through multiple cycles beforehand to serve it to shortsellers. The financing prior to data release (to come) and deal-making was done with a vulture financier (no choice at this stage) but the language explicitly ensured 'no shorting or hedging' (we'll see). The CEO worked at Deutsche Bank before and knows the ropes.....and we have Leo.
Long and strong CTIX............still keeping the faith.
Parkinson's victims 'brought back to life': Cancer drug's amazing effect echoes Awakenings film
Leukaemia drug nilotinib helped advanced Parkinson's disease patients
Scientists said those given it for a research study had 'come back to life'
One wheelchair-bound patient able to walk again, others regained speech
Researchers now hope ‘life-changing’ drug will help those with Alzheimer's
By Fiona Macrae Science Correspondent For The Daily Mail
Parkinson's patients 'walk and talk again' after receiving cancer drug in trial
a) today with prelim P2a pt A so far (my guess=$6.5)
b) after Oct 7 with full P2a pt A and informal initial P2a pt B data (my guess=$13-14 pop with a fade to $10)